25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HBPCF (Helix BioPharma Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Helix BioPharma Corp together

I guess you are interested in Helix BioPharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Helix BioPharma Corp’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Helix BioPharma Corp’s Price Targets

I'm going to help you getting a better view of Helix BioPharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Helix BioPharma Corp

I send you an email if I find something interesting about Helix BioPharma Corp.

1. Quick Overview

1.1. Quick analysis of Helix BioPharma Corp (30 sec.)










1.2. What can you expect buying and holding a share of Helix BioPharma Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$0.01
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$0.01
Return On Investment
0.6%

For what price can you sell your share?

Current Price per Share
$1.73
Expected price per share
$0.92 - $1.73
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Helix BioPharma Corp (5 min.)




Live pricePrice per Share (EOD)
$1.73
Intrinsic Value Per Share
$-0.35 - $-0.02
Total Value Per Share
$-0.35 - $-0.02

2.2. Growth of Helix BioPharma Corp (5 min.)




Is Helix BioPharma Corp growing?

Current yearPrevious yearGrowGrow %
How rich?-$63.7k-$597.9k$534.2k837.8%

How much money is Helix BioPharma Corp making?

Current yearPrevious yearGrowGrow %
Making money-$6.5k-$4.4m$4.4m67,797.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Helix BioPharma Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#713 / 843

Most Revenue
#744 / 843

Most Profit
#168 / 843

Most Efficient
#237 / 843
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Helix BioPharma Corp?

Welcome investor! Helix BioPharma Corp's management wants to use your money to grow the business. In return you get a share of Helix BioPharma Corp.

First you should know what it really means to hold a share of Helix BioPharma Corp. And how you can make/lose money.

Speculation

The Price per Share of Helix BioPharma Corp is $1.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Helix BioPharma Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Helix BioPharma Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Helix BioPharma Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.0%0.000.0%-0.02-1.3%-0.02-1.0%-0.03-1.7%-0.05-2.8%
Usd Book Value Change Per Share0.000.1%0.000.1%0.00-0.3%0.000.1%0.000.2%-0.01-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.1%0.000.1%0.00-0.3%0.000.1%0.000.2%-0.01-0.4%
Usd Price Per Share0.17-0.17-0.14-0.15-0.32-14.31-
Price to Earnings Ratio-2,887.29--2,887.29--6.07--966.06--584.73--473.48-
Price-to-Total Gains Ratio67.39-67.39--30.39-18.10-6.87--6,718.14-
Price to Book Ratio-297.20--297.20--45.24--81.08--63.93--33,730.62-
Price-to-Total Gains Ratio67.39-67.39--30.39-18.10-6.87--6,718.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.73
Number of shares578
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (578 shares)1.462.45
Gains per Year (578 shares)5.839.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
106-40100
2012202010
3017802920
40231403930
50292004940
60352605950
70413206960
80473807970
90524408880
100585009890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.018.07.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%3.07.00.030.0%12.013.00.048.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.025.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%3.07.00.030.0%12.013.00.048.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Helix BioPharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0030.0030%-0.005+283%0.002+15%0.004-41%-0.006+353%
Book Value Per Share---0.001-0.0010%-0.003+441%-0.001+26%0.001-140%0.006-109%
Current Ratio--0.9220.9220%0.531+73%0.846+9%1.199-23%1.817-49%
Debt To Asset Ratio--1.0601.0600%1.820-42%1.265-16%1.106-4%1.378-23%
Debt To Equity Ratio----0%-0%3.564-100%2.299-100%1.205-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--18598014.58018598014.5800%26297464.240-29%22401954.157-17%43573202.658-57%1327683783.628-99%
Eps--0.0000.0000%-0.023+39071%-0.018+30600%-0.029+49281%-0.049+83615%
Ev To Ebitda Ratio---2845.512-2845.5120%-5.879-100%-952.072-67%-576.067-80%-522.387-82%
Free Cash Flow Per Share---0.033-0.0330%-0.020-39%-0.028-15%-0.038+16%-0.051+53%
Free Cash Flow To Equity Per Share--0.0020.0020%-0.009+618%-0.003+267%-0.002+218%-0.006+474%
Gross Profit Margin--1.0001.0000%1.119-11%1.040-4%1.024-2%1.012-1%
Intrinsic Value_10Y_max---0.023----------
Intrinsic Value_10Y_min---0.348----------
Intrinsic Value_1Y_max---0.023----------
Intrinsic Value_1Y_min---0.047----------
Intrinsic Value_3Y_max---0.052----------
Intrinsic Value_3Y_min---0.132----------
Intrinsic Value_5Y_max---0.064----------
Intrinsic Value_5Y_min---0.205----------
Market Cap132134109.540+86%18950847.58018950847.5800%27052016.740-30%22808633.157-17%43758121.158-57%1195135890.465-98%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio-3024.429-918%-297.198-297.1980%-45.239-85%-81.075-73%-63.926-78%-33730.619+11250%
Pe Ratio-29382.410-918%-2887.289-2887.2890%-6.070-100%-966.060-67%-584.728-80%-473.482-84%
Price Per Share1.730+90%0.1700.1700%0.140+21%0.153+11%0.316-46%14.308-99%
Price To Free Cash Flow Ratio-52.016-918%-5.111-5.1110%-6.896+35%-5.623+10%-7.716+51%-190.969+3636%
Price To Total Gains Ratio685.791+90%67.39067.3900%-30.391+145%18.100+272%6.870+881%-6718.136+10069%
Quick Ratio--0.7190.7190%0.464+55%0.740-3%1.087-34%1.719-58%
Return On Assets---0.006-0.0060%-6.113+98150%-2.626+42110%-2.337+37470%-3.510+56309%
Return On Equity----0%-0%-6.8580%-4.8650%-2.8660%
Total Gains Per Share--0.0030.0030%-0.005+283%0.002+15%0.004-41%-0.006+353%
Usd Book Value---63765.000-63765.0000%-597974.000+838%-145242.500+128%137874.100-146%434948.150-115%
Usd Book Value Change Per Share--0.0030.0030%-0.005+283%0.002+15%0.004-41%-0.006+353%
Usd Book Value Per Share---0.001-0.0010%-0.003+441%-0.001+26%0.001-140%0.006-109%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--18598014.58018598014.5800%26297464.240-29%22401954.157-17%43573202.658-57%1327683783.628-99%
Usd Eps--0.0000.0000%-0.023+39071%-0.018+30600%-0.029+49281%-0.049+83615%
Usd Free Cash Flow---3707580.500-3707580.5000%-3922964.500+6%-4080723.833+10%-5303122.500+43%-5498597.650+48%
Usd Free Cash Flow Per Share---0.033-0.0330%-0.020-39%-0.028-15%-0.038+16%-0.051+53%
Usd Free Cash Flow To Equity Per Share--0.0020.0020%-0.009+618%-0.003+267%-0.002+218%-0.006+474%
Usd Market Cap132134109.540+86%18950847.58018950847.5800%27052016.740-30%22808633.157-17%43758121.158-57%1195135890.465-98%
Usd Price Per Share1.730+90%0.1700.1700%0.140+21%0.153+11%0.316-46%14.308-99%
Usd Profit---6563.544-6563.5440%-4456465.000+67797%-3037638.015+46180%-4234741.909+64419%-5277635.204+80308%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share--0.0030.0030%-0.005+283%0.002+15%0.004-41%-0.006+353%
 EOD+7 -1MRQTTM+0 -0YOY+21 -103Y+21 -115Y+15 -1710Y+18 -14

3.3 Fundamental Score

Let's check the fundamental score of Helix BioPharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-29,382.410
Price to Book Ratio (EOD)Between0-1-3,024.429
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.719
Current Ratio (MRQ)Greater than10.922
Debt to Asset Ratio (MRQ)Less than11.060
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.006
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Helix BioPharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than50100.000
Ma 20Greater thanMa 501.222
Ma 50Greater thanMa 1000.849
Ma 100Greater thanMa 2000.724
OpenGreater thanClose1.730
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Helix BioPharma Corp

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2025-11-06 10:45:08.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Helix BioPharma Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--77.9%+77.9%
TTM--163.3%+163.3%
YOY--187.9%+187.9%
3Y--262.6%+262.6%
5Y--338.6%+338.6%
10Y--470.4%+470.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Helix BioPharma Corp is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • -0.6% Return on Assets means thatΒ Helix BioPharma Corp generatedΒ $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Helix BioPharma Corp:

  • The MRQ is -0.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.6%TTM-0.6%0.0%
TTM-0.6%YOY-611.3%+610.7%
TTM-0.6%5Y-233.7%+233.1%
5Y-233.7%10Y-351.0%+117.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.6%-11.9%+11.3%
TTM-0.6%-11.5%+10.9%
YOY-611.3%-11.2%-600.1%
3Y-262.6%-12.0%-250.6%
5Y-233.7%-11.6%-222.1%
10Y-351.0%-13.7%-337.3%
4.3.1.3. Return on Equity

Shows how efficient Helix BioPharma Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Helix BioPharma Corp generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-486.5%+486.5%
5Y-486.5%10Y-286.6%-199.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.9%+13.9%
TTM--14.7%+14.7%
YOY--15.1%+15.1%
3Y-685.8%-16.7%-669.1%
5Y-486.5%-16.9%-469.6%
10Y-286.6%-19.5%-267.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Helix BioPharma Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Helix BioPharma Corp is operatingΒ .

  • Measures how much profit Helix BioPharma Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--164.9%+164.9%
TTM--268.1%+268.1%
YOY--249.5%+249.5%
3Y--248.8%+248.8%
5Y--331.9%+331.9%
10Y--501.5%+501.5%
4.3.2.2. Operating Ratio

Measures how efficient Helix BioPharma Corp is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.891-1.891
TTM-2.722-2.722
YOY-2.848-2.848
3Y-3.562-3.562
5Y-4.571-4.571
10Y-6.306-6.306
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Helix BioPharma Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.92Β means the company has $0.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.922. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.922. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.922TTM0.9220.000
TTM0.922YOY0.531+0.391
TTM0.9225Y1.199-0.277
5Y1.19910Y1.817-0.618
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9223.272-2.350
TTM0.9223.570-2.648
YOY0.5314.010-3.479
3Y0.8464.376-3.530
5Y1.1995.701-4.502
10Y1.8176.070-4.253
4.4.3.2. Quick Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.72Β means the company can pay off $0.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.719. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.719. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.719TTM0.7190.000
TTM0.719YOY0.464+0.255
TTM0.7195Y1.087-0.369
5Y1.08710Y1.719-0.632
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7192.909-2.190
TTM0.7193.149-2.430
YOY0.4643.831-3.367
3Y0.7404.393-3.653
5Y1.0875.686-4.599
10Y1.7196.469-4.750
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Helix BioPharma Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Helix BioPharma CorpΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Helix BioPharma Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.06Β means that Helix BioPharma Corp assets areΒ financed with 106.0% credit (debt) and the remaining percentage (100% - 106.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Helix BioPharma Corp:

  • The MRQ is 1.060. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.060. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.060TTM1.0600.000
TTM1.060YOY1.820-0.760
TTM1.0605Y1.106-0.046
5Y1.10610Y1.378-0.272
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0600.350+0.710
TTM1.0600.364+0.696
YOY1.8200.335+1.485
3Y1.2650.353+0.912
5Y1.1060.348+0.758
10Y1.3780.379+0.999
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Helix BioPharma Corp is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.299-2.299
5Y2.29910Y1.205+1.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.410-0.410
TTM-0.448-0.448
YOY-0.431-0.431
3Y3.5640.473+3.091
5Y2.2990.474+1.825
10Y1.2050.523+0.682
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Helix BioPharma Corp generates.

  • Above 15 is considered overpriced butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A PE ratio of -2,887.29 means the investor is paying $-2,887.29Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Helix BioPharma Corp:

  • The EOD is -29,382.410. Based on the earnings, the company is expensive. -2
  • The MRQ is -2,887.289. Based on the earnings, the company is expensive. -2
  • The TTM is -2,887.289. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29,382.410MRQ-2,887.289-26,495.121
MRQ-2,887.289TTM-2,887.2890.000
TTM-2,887.289YOY-6.070-2,881.219
TTM-2,887.2895Y-584.728-2,302.561
5Y-584.72810Y-473.482-111.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-29,382.410-2.847-29,379.563
MRQ-2,887.289-2.294-2,884.995
TTM-2,887.289-2.664-2,884.625
YOY-6.070-3.550-2.520
3Y-966.060-3.737-962.323
5Y-584.728-5.932-578.796
10Y-473.482-6.842-466.640
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Helix BioPharma Corp:

  • The EOD is -52.016. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.111. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.111. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-52.016MRQ-5.111-46.904
MRQ-5.111TTM-5.1110.000
TTM-5.111YOY-6.896+1.784
TTM-5.1115Y-7.716+2.605
5Y-7.71610Y-190.969+183.253
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-52.016-3.522-48.494
MRQ-5.111-2.907-2.204
TTM-5.111-3.820-1.291
YOY-6.896-4.330-2.566
3Y-5.623-5.303-0.320
5Y-7.716-8.242+0.526
10Y-190.969-9.764-181.205
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Helix BioPharma Corp is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -297.20 means the investor is paying $-297.20Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Helix BioPharma Corp:

  • The EOD is -3,024.429. Based on the equity, the company is expensive. -2
  • The MRQ is -297.198. Based on the equity, the company is expensive. -2
  • The TTM is -297.198. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3,024.429MRQ-297.198-2,727.231
MRQ-297.198TTM-297.1980.000
TTM-297.198YOY-45.239-251.959
TTM-297.1985Y-63.926-233.272
5Y-63.92610Y-33,730.619+33,666.693
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3,024.4292.396-3,026.825
MRQ-297.1982.061-299.259
TTM-297.1982.224-299.422
YOY-45.2392.489-47.728
3Y-81.0752.654-83.729
5Y-63.9263.764-67.690
10Y-33,730.6194.406-33,735.025
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-07-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets1,489
Total Liabilities1,579
Total Stockholder Equity-90
 As reported
Total Liabilities 1,579
Total Stockholder Equity+ -90
Total Assets = 1,489

Assets

Total Assets1,489
Total Current Assets1,456
Long-term Assets33
Total Current Assets
Cash And Cash Equivalents 1,081
Net Receivables 54
Other Current Assets 321
Total Current Assets  (as reported)1,456
Total Current Assets  (calculated)1,456
+/-0
Long-term Assets
Property Plant Equipment 33
Intangible Assets 1
Long-term Assets Other -1
Long-term Assets  (as reported)33
Long-term Assets  (calculated)33
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,579
Long-term Liabilities0
Total Stockholder Equity-90
Total Current Liabilities
Accounts payable 855
Other Current Liabilities 724
Total Current Liabilities  (as reported)1,579
Total Current Liabilities  (calculated)1,579
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock158,572
Retained Earnings -210,671
Other Stockholders Equity 52,009
Total Stockholder Equity (as reported)-90
Total Stockholder Equity (calculated)-90
+/-0
Other
Capital Stock158,572
Cash and Short Term Investments 1,081
Common Stock Shares Outstanding 111,476
Liabilities and Stockholders Equity 1,489
Net Debt -1,081
Net Invested Capital -90
Net Working Capital -123
Property Plant and Equipment Gross 1,838



6.2. Balance Sheets Structured

Currency in CAD. All numbers in thousands.

 Trend2024-07-312023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-312016-07-312015-07-312014-07-312013-07-312012-07-312011-07-312010-07-312009-07-312008-07-312007-07-312006-07-312005-07-312004-07-312003-07-312002-07-312001-07-312000-07-31
> Total Assets 
9,875
11,930
9,047
11,491
9,388
9,448
13,668
14,273
21,666
19,319
18,114
24,371
7,616
5,868
7,853
7,796
4,468
2,187
1,147
940
4,906
4,065
3,730
1,029
1,489
1,4891,0293,7304,0654,9069401,1472,1874,4687,7967,8535,8687,61624,37118,11419,31921,66614,27313,6689,4489,38811,4919,04711,9309,875
   > Total Current Assets 
0
0
0
0
0
0
0
13,007
20,310
17,454
15,668
21,680
6,123
5,191
7,405
7,467
4,233
1,700
773
687
4,660
4,018
3,695
996
1,456
1,4569963,6954,0184,6606877731,7004,2337,4677,4055,1916,12321,68015,66817,45420,31013,0070000000
       Cash And Cash Equivalents 
2,039
2,518
1,928
1,342
2,699
3,408
3,881
11,379
19,057
14,494
13,125
19,044
4,862
4,493
6,980
6,792
3,654
897
366
206
4,235
3,565
3,252
808
1,081
1,0818083,2523,5654,2352063668973,6546,7926,9804,4934,86219,04413,12514,49419,05711,3793,8813,4082,6991,3421,9282,5182,039
       Short-term Investments 
6,148
6,932
5,409
4,931
2,241
2,038
5,867
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000005,8672,0382,2414,9315,4096,9326,148
       Net Receivables 
0
0
0
0
0
0
0
902
349
1,053
1,365
1,906
733
559
343
491
489
630
315
290
13
353
280
62
54
5462280353132903156304894913435597331,9061,3651,0533499020000000
       Other Current Assets 
118
97
134
170
136
234
141
187
446
1,049
398
202
107
139
82
184
90
173
92
191
412
100
164
126
321
3211261641004121919217390184821391072023981,04944618714123413617013497118
   > Long-term Assets 
0
0
0
0
0
0
0
1,266
1,356
1,865
2,446
2,691
1,493
677
448
329
235
487
374
253
246
47
35
33
33
333335472462533744872353294486771,4932,6912,4461,8651,3561,2660000000
       Property Plant Equipment 
460
867
695
885
1,009
1,172
1,204
1,139
1,151
1,809
1,987
2,031
1,049
677
448
329
235
487
374
253
246
47
35
33
33
333335472462533744872353294486771,0492,0311,9871,8091,1511,1391,2041,1721,009885695867460
       Long Term Investments 
0
0
0
0
0
0
0
0
0
52
436
723
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000072343652000000000
       Intangible Assets 
151
134
114
3,649
2,914
1,824
1,429
126
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
10000000000000001101261,4291,8242,9143,649114134151
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
459
660
444
0
0
0
0
0
0
0
0
0
1
0
-1
-1010000000004446604590000000000
> Total Liabilities 
926
718
704
520
969
947
1,403
1,539
1,144
2,256
2,353
2,258
1,392
948
1,042
969
1,304
2,204
2,674
4,221
1,925
5,458
3,411
1,873
1,579
1,5791,8733,4115,4581,9254,2212,6742,2041,3049691,0429481,3922,2582,3532,2561,1441,5391,403947969520704718926
   > Total Current Liabilities 
763
616
632
469
941
932
1,403
1,539
1,144
2,158
2,281
2,210
1,369
948
1,042
969
1,304
2,204
2,674
4,221
1,925
3,874
3,411
1,874
1,579
1,5791,8743,4113,8741,9254,2212,6742,2041,3049691,0429481,3692,2102,2812,1581,1441,5391,403932941469632616763
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
2,028
2,468
0
0
002,4682,02815900000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,028
2,468
0
0
002,4682,028000000000000000000000
       Accounts payable 
739
591
609
443
922
875
1,389
565
598
1,299
1,392
1,085
650
304
566
262
715
1,438
1,992
3,040
1,416
1,466
599
493
855
8554935991,4661,4163,0401,9921,4387152625663046501,0851,3921,2995985651,389875922443609591739
       Other Current Liabilities 
0
0
0
0
0
41
0
974
546
859
889
829
719
644
476
707
589
722
644
1,057
350
380
344
1,381
724
7241,3813443803501,05764472258970747664471982988985954697404100000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
98
72
48
23
0
0
0
0
0
0
0
0
1,584
0
-1
0
0-101,5840000000023487298000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
91
70
50
23
0
0
0
0
0
0
0
0
0
0
0
0
00000000000023507091000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
91
68
52
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000526891000000000
> Total Stockholder Equity
8,814
10,801
8,113
10,971
8,419
8,501
12,265
12,734
20,522
17,063
15,761
22,113
6,224
4,920
6,811
6,827
3,164
-17
-1,527
-3,281
2,394
-1,393
319
-844
-90
-90-844319-1,3932,394-3,281-1,527-173,1646,8276,8114,9206,22422,11315,76117,06320,52212,73412,2658,5018,41910,9718,11310,8018,814
   Common Stock
15,829
20,676
20,016
26,372
28,910
35,952
45,895
53,734
70,312
75,673
88,661
106,878
102,077
101,407
107,079
112,288
116,146
120,681
125,565
129,532
137,257
139,660
147,511
152,068
158,572
158,572152,068147,511139,660137,257129,532125,565120,681116,146112,288107,079101,407102,077106,87888,66175,67370,31253,73445,89535,95228,91026,37220,01620,67615,829
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
94
55
0
0
0
13
17
12
10,549
11,814
14,045
15,403
20,113
19,634
10,335
4,357
0
04,35710,33519,63420,11315,40314,04511,81410,549121713000559400000000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
64,462
79,120
88,332
103,024
121,389
20,530
21,757
26,658
30,195
32,339
34,682
36,913
38,718
25,540
47,501
47,925
48,494
52,009
52,00948,49447,92547,50125,54038,71836,91334,68232,33930,19526,65821,75720,530121,389103,02488,33279,12064,4620000000



6.3. Balance Sheets

Currency in CAD. All numbers in thousands.




6.4. Cash Flows

Currency in CAD. All numbers in thousands.




6.5. Income Statements

Currency in CAD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-07-31. Currency in CAD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-9
Operating Income-9-9
 
Operating Expense (+$)
Research Development6
Selling General Administrative2,575
Selling And Marketing Expenses-
Operating Expense92,581
 
Net Interest Income (+$)
Interest Income31
Interest Expense-7
Other Finance Cost-0
Net Interest Income24
 
Pretax Income (+$)
Operating Income-9
Net Interest Income24
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-9-9
EBIT - interestExpense = -16
-9
-2
Interest Expense7
Earnings Before Interest and Taxes (EBIT)-9-2
Earnings Before Interest and Taxes (EBITDA)-9
 
After tax Income (+$)
Income Before Tax-9
Tax Provision--
Net Income From Continuing Ops-9,264-9
Net Income-9
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses9
Total Other Income/Expenses Net0-24
 

Technical Analysis of Helix BioPharma Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Helix BioPharma Corp. The general trend of Helix BioPharma Corp is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Helix BioPharma Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Helix BioPharma Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Helix BioPharma Corp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.73 < 1.73 < 1.73.

The bearish price targets are: 1.73 > 0.92 > 0.92.

Know someone who trades $HBPCF? Share this with them.πŸ‘‡

Helix BioPharma Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Helix BioPharma Corp. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Helix BioPharma Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Helix BioPharma Corp. The current macd is 0.30474654.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Helix BioPharma Corp price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Helix BioPharma Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Helix BioPharma Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Helix BioPharma Corp Daily Moving Average Convergence/Divergence (MACD) ChartHelix BioPharma Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Helix BioPharma Corp. The current adx is 99.95.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Helix BioPharma Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Helix BioPharma Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Helix BioPharma Corp. The current sar is 1.08251587.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Helix BioPharma Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Helix BioPharma Corp. The current rsi is 100.00. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
Helix BioPharma Corp Daily Relative Strength Index (RSI) ChartHelix BioPharma Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Helix BioPharma Corp. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Helix BioPharma Corp price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Helix BioPharma Corp Daily Stochastic Oscillator ChartHelix BioPharma Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Helix BioPharma Corp. The current cci is 60.61.

Helix BioPharma Corp Daily Commodity Channel Index (CCI) ChartHelix BioPharma Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Helix BioPharma Corp. The current cmo is 100.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Helix BioPharma Corp Daily Chande Momentum Oscillator (CMO) ChartHelix BioPharma Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Helix BioPharma Corp. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Helix BioPharma Corp Daily Williams %R ChartHelix BioPharma Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Helix BioPharma Corp.

Helix BioPharma Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Helix BioPharma Corp. The current atr is 0.03846889.

Helix BioPharma Corp Daily Average True Range (ATR) ChartHelix BioPharma Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Helix BioPharma Corp. The current obv is 6,029.

Helix BioPharma Corp Daily On-Balance Volume (OBV) ChartHelix BioPharma Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Helix BioPharma Corp. The current mfi is 100.00.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Helix BioPharma Corp Daily Money Flow Index (MFI) ChartHelix BioPharma Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Helix BioPharma Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-24STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Helix BioPharma Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Helix BioPharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than50100.000
Ma 20Greater thanMa 501.222
Ma 50Greater thanMa 1000.849
Ma 100Greater thanMa 2000.724
OpenGreater thanClose1.730
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Helix BioPharma Corp with someone you think should read this too:
  • Are you bullish or bearish on Helix BioPharma Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Helix BioPharma Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Helix BioPharma Corp

I send you an email if I find something interesting about Helix BioPharma Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Helix BioPharma Corp.

Receive notifications about Helix BioPharma Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.